spacer
home > ict > autumn 2020 > accelerating processes and enhancing compliance with pharmacovigilance automation
PUBLICATIONS
International Clinical Trials

Accelerating Processes and Enhancing Compliance with Pharmacovigilance Automation

Adverse event (AE) information comes from healthcare professionals, manufacturers, and patients themselves, producing a huge volume of data to analyse. Life science organisations face a daily challenge capturing this information, assessing its significance, and reporting it to the authorities in a timely manner, so that safety information can be updated and, if appropriate, additional action can be taken.

It is clear that pharmaceutical companies should be harnessing the latest technology to capture and process the workloads. The range of technology options are considerable, and the technology is proven, reliable, and highly cost-efficient. However, it does appear that companies could be doing so much more with technology.

Many pharma companies believe they are making good use of technology for AE data capture and reporting, according to a recent survey. The research examines life science companies’ attitudes towards, and plans for, pharmacovigilance (PV) automation, particularly

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr John Price, owner and Managing Director of John Price PharmaSolutions LLC, is a life science regulatory and safety veteran and consultant, and an advisor to PV managed service provider Arriello.

drjsprice@pharmacovigilantes.com
Print this page
Send to a friend
Privacy statement
News and Press Releases

Virisure & Bionique Join Forces

VIENNA, AUSTRIA – 15th December 2021 – Asahi Kasei Medical Co., Ltd (Asahi Kasei Medical) announced today the acquisition of Bionique Testing Laboratories LLC, a US-based leader in mycoplasma testing services for the biologics and life-sciences industries. Bionique joins ViruSure GmbH as part of the global biosafety testing services unit of Asahi Kasei Medical’s Bioprocess Division. Both Bionique and ViruSure will continue operations under their existing, widely respected brands.
More info >>

White Papers
 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement